RHHBY to Advance Parkinson's Disease Drug to Late-Stage Development [Yahoo! Finance]
Prothena Corporation plc - Ordinary Shares (PRTA)
Last prothena corporation plc - ordinary shares earnings: 2/12 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.prothena.com
Company Research
Source: Yahoo! Finance
Roche has a licensing agreement with Prothena PRTA for prasinezumab. The decision to advance prasinezumab to late-stage development was based on data from the phase IIb PADOVA study and ongoing open-label extensions (OLEs) of PADOVA and phase II PASADENA studies. Year to date, shares of Roche have risen 20.9% compared to the industry's 4% growth. Image Source: Zacks Investment Research Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson's disease progression. The ongoing PASADENA and PADOVA OLE studies are evaluating the long-term safety and efficacy of prasinezumab in over 750 people with early-stage Parkinson's disease. Multiple endpoints from the PADOVA and OLE studies indicate a potential clinical benefit of prasinezumab when added to effective symptomatic treatment in early-stage Parkinson's disease. The phase IIb PADOVA study evaluated the safety and efficacy of prasinezumab versus placebo in 5
Show less
Read more
Impact Snapshot
Event Time:
PRTA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRTA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRTA alerts
High impacting Prothena Corporation plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
PRTA
News
- Prothena Announces Board of Directors Update [Yahoo! Finance]Yahoo! Finance
- Prothena Announces Board of Directors UpdateBusiness Wire
- How the Narrative Surrounding Prothena Is Changing After New Pipeline and Valuation Updates [Yahoo! Finance]Yahoo! Finance
- Prothena (NASDAQ:PRTA) had its price target raised by analysts at Citizens Jmp from $11.00 to $19.00. They now have a "market outperform" rating on the stock.MarketBeat
- Prothena (NASDAQ:PRTA) was given a new $19.00 price target on by analysts at Deutsche Bank Aktiengesellschaft.MarketBeat
PRTA
Earnings
- 11/6/25 - Miss
PRTA
Sec Filings
- 12/12/25 - Form 8-K
- 11/19/25 - Form 8-K
- 11/14/25 - Form SCHEDULE
- PRTA's page on the SEC website